Olema Oncology to Participate in Upcoming Investor Conferences in May
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will participate in various investor conferences in May, including the BofA Securities Health Care Conference, H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will participate in various investor conferences in May, including the BofA Securities Health Care Conference, H.C. Wainwright BioConnect Investor Conference, UBS Spring Biotech Symposium, and TD Cowen Oncology Innovation Summit. The management team will engage in presentations, fireside chats, and one-on-one meetings to discuss the company's targeted therapies for women's cancers.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was +2.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:
BofA Securities Health Care Conference 2024
Date: Tuesday, May 14, 2024, at 4:35 p.m. PT
Location: Encore Hotel in Las Vegas, NV
Format: Presentation
H.C. Wainwright 2nd Annual BioConnect Investor Conference
Date: Monday, May 20, 2024, at 4:00 p.m. ET
Location: NASDAQ Headquarters in New York, NY
Format: Fireside Chat
UBS Spring Biotech Symposium
Date: Tuesday, May 21, 2024
Location: New York, NY
Format: One-on-one Meetings
TD Cowen 5th Annual Oncology Innovation Summit
Date: Tuesday, May 28, 2024, at 10:00 a.m. ET
Location: Virtual
Format: Fireside Chat
Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
ir@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.